Table 1.
Include the basic characteristics of the literature.
| Study | Year | Design study | Area | Infection group | Non-infection group | Risk factors |
|---|---|---|---|---|---|---|
| Raffenberg et al. (10) | 2001 | Case-control | Germany | 16 | 95 | 06, 13, 14, 16, 17, 21 |
| Dai et al. (11) | 2006 | Case-control | China | 48 | 48 | 01, 02, 04, 13, 14, 16, 18, 19 |
| Nseir et al. (12) | 2006 | Case-control | France | 30 | 60 | 01, 02, 05, 06, 07, 10, 13, 15, 16, 17 |
| Ansari et al. (13) | 2007 | Case-control | USA | 54 | 108 | 01, 02, 04, 08, 09, 21, 23, 24, 25 |
| Xu et al. (14) | 2011 | Case-control | China | 35 | 140 | 01, 02, 03, 13, 14, 15, 18, 21, 23, 26 |
| Mutlu et al. (15) | 2011 | Case-control | Turkey | 23 | 45 | 02, 04, 05, 13, 17, 21, 23 |
| Saugel et al. (16) | 2012 | Case-control | Germany | 36 | 28 | 02, 06, 07, 08, 10, 15, 16, 17 |
| Peng and Liu (17) | 2013 | Case-control | China | 30 | 30 | 01, 02, 04, 21 |
| Guo et al. (18) | 2014 | Case-control | China | 42 | 84 | 01, 02, 03, 04, 06, 07, 10, 13, 14, 15, 18, 26 |
| Lv and Zhang (19) | 2014 | Case-control | China | 238 | 476 | 02, 03, 05, 06, 07, 08, 10, 12, 21, 22, 23, 24, 26 |
| Hottal et al. (20) | 2014 | Case-control | Japan | 54 | 167 | 02, 07, 08, 09, 10, 11, 12, 13, 16, 17, 18, 20, 21, 23, 25 |
| Cha (21) | 2015 | Case-control | China | 60 | 120 | 01, 02, 06, 07, 08, 10, 11, 12, 13, 16, 17, 20, 21, 22, 23, 24, 25 |
| Cabaret et al. (22) | 2016 | Case-control | France | 20 | 237 | 01, 02, 04, 06, 08, 09, 12, 14, 16, 19 |
| Proceedings of reanimation (23) | 2018 | Case-control | France | 93 | 380 | 04, 09, 10, 12, 16, 19, 21, 25 |
| Liu et al. (24) | 2018 | Case-control | China | 90 | 30 | 01, 02, 04, 05, 07, 08, 10, 13, 15, 16, 20, 21, 26 |
| Shi et al. (25) | 2019 | Case-control | China | 29 | 58 | 01, 02, 04, 05, 07, 08, 09, 10, 12, 13, 16, 17, 19, 21, 23, 24, 25 |
| Ibn Saied et al. (26) | 2019 | Case-control | France | 102 | 1,492 | 02, 04, 10, 11, 12 |
| Imoto et al. (27) | 2021 | Case-control | Japan | 8 | 91 | 02, 04, 08, 16, 18, 20, 22 |
01, Age, years; 02, Gender; 03, APACHE-II score >20; 04, Glucocorticoid; 05, Hospitalization days; 06, COPD; 07, Diabetes; 08, Solid malignant tumors; 09, Malignant tumors of the hematologic system; 10, Cardiovascular disease; 11, Kidney dysfunction; 12, Immunosuppression; 13, Mechanical ventilation; 14, Tracheal intubation; 15, Tracheotomy; 16, Central venous catheterization; 17, Urinary catheter; 18, Nasogastric tube; 19, Parenteral nutrition; 20, Operation; 21, Carbapenems; 22, β-lactamase inhibitor; 23, Aminoglycosides; 24, Quinolones; 25, Glycopeptides; 26, Use more than 3 kinds of antibacterial drugs.